FDA Approval of Taletrectinib for ROS1+ NSCLC: Dr. Liu Weighs In
Stephen Liu, MD, shares his insights on the recent FDA approval of taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC).
Related Articles
The HemOnc Pulse | Blood Cancers Today
The HemOnc Pulse podcast covers all things hematologic oncology.
Enlicitide Decanoate Demonstrates Meaningful Reductions in LDL-C
In two phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial hypercholesterolemia.
Predictors of treatment-emergent resistance to dolutegravir
Integrase strand transfer inhibitor (INSTI)-based regimens became a first-line treatment for HIV worldwide in 2018, with 93% of people with HIV who are on antiretroviral…
ASCO 2025 – Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain were joined by Dr. Erika Hamilton from the Sarah Cannon Research Institute,…
2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health: A Report of the American College of Cardiology Solution Set Oversight Committee
Gurusher S. Panjrath, MBBS, FACC, Chair Nicole M. Bhave, MD, FACC, Immediate Past Chair ∗ Chayakrit Krittanawong, MD, FACC Barbara Wiggins, P harm D, FACC…
https://www.lls.org/treatment/follow-care-and-survivorship/resources-survivors
Use this Survivorship Workbook to collect all the important information you need throughout diagnosis, treatment, follow-up care and long-term management of a blood cancer. Support…
People.com | Celebrity News, Exclusives, Photos and Videos
Get breaking news and trending scoops on your favorite celebs, royals, true crime sagas, and more.
Novel Interferon-Based Agent Compares Favorably with Anagrelide in Essential Thrombocythemia | Docwire News
The SURPASS ET trial evaluated efficacy and safety of ropeginterferon alfa-2b in second-line ET treatment.
Does Knowledge of the Calcium CT Score Improve Patient Outcomes?: Joel Kahn, MD: Integrative Cardiologist
The combination of CAC score with a primary prevention strategy in intermediate-risk patients with a family history of CAD was associated with reduction of athe